Search research articles
Contact Us
Filters
Showing results (31-40 of 85) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Konrad H Stopsack, Subhiksha Nandakumar, Andreas G Wibmer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 27, 2024
<i>RAD21</i> promotes oncogenesis and lethal progression of prostate cancer
Xiaofeng A Su, Konrad H Stopsack, Daniel R Schmidt, et al.
The Journal of Urology
|
March 28, 2023
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients
Kelsey E Breen, Heather Symecko, Kelsey Spielman, et al.
British Journal of Cancer
|
November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.
Cancer Research Communications
|
June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study
Rahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
Nature Communications
|
April 20, 2022
AKT mutant allele-specific activation dictates pharmacologic sensitivities
Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N Gorelick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Wassim Abida, Andrew W Hahn, Neal Shore, et al.
NPJ Precision Oncology
|
February 14, 2024
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
Charlotte S Walmsley, Philip Jonsson, Michael L Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2021
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Konrad H Stopsack, Subhiksha Nandakumar, Kanika Arora, et al.
JCO Precision Oncology
|
March 18, 2026
Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer
Jeffery C W Chang, Subhiksha Nandakumar, Konrad H Stopsack, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 85) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Konrad H Stopsack, Subhiksha Nandakumar, Andreas G Wibmer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 27, 2024
<i>RAD21</i> promotes oncogenesis and lethal progression of prostate cancer
Xiaofeng A Su, Konrad H Stopsack, Daniel R Schmidt, et al.
The Journal of Urology
|
March 28, 2023
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients
Kelsey E Breen, Heather Symecko, Kelsey Spielman, et al.
British Journal of Cancer
|
November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.
Cancer Research Communications
|
June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study
Rahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
Nature Communications
|
April 20, 2022
AKT mutant allele-specific activation dictates pharmacologic sensitivities
Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N Gorelick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Wassim Abida, Andrew W Hahn, Neal Shore, et al.
NPJ Precision Oncology
|
February 14, 2024
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
Charlotte S Walmsley, Philip Jonsson, Michael L Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2021
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Konrad H Stopsack, Subhiksha Nandakumar, Kanika Arora, et al.
JCO Precision Oncology
|
March 18, 2026
Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer
Jeffery C W Chang, Subhiksha Nandakumar, Konrad H Stopsack, et al.
Page
of 9